Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

This trial is studying the best treatment strategies and survival outcomes for patients with advanced (stage IV) non-small cell lung cancer that carries specific gene mutations (such as EGFR, ALK, or ROS1) that can be targeted with precision medicines. You may be eligible if: you are 18 or older; you have confirmed stage IV non-small cell lung cancer with a targetable gene mutation; your cancer is measurable on scans; your expected survival is at least 12 weeks; and your organ function is adequate. You may NOT be eligible if: your health does not meet the baseline requirements listed above. Talk to your doctor to see if this trial is right for you.